The folks at PepGen certainly showed some courage earlier this month when they chose to proceed with their initial public offering.
On May 5, the development-stage biopharma company sold nine million shares at $12 a pop. It had hoped to offer 7.2 million shares between $13 and $15 a share, according to a regulatory filing.
The
